Company overview
Enzymit develops a cell-free biomanufacturing platform using AI-designed enzymes to produce high-purity hyaluronic acid (HA) and specialty carbohydrates from simple sugars. Their GMP-ready, animal-free process delivers pharmaceutical- and cosmetic-grade HA with selectable molecular weights from 20 kDa to 4 MDa, low endotoxin levels (≤0.05 EU/mg), and ≥99% purity. This technology scales linearly from kg to tonnes, reducing water, energy, and CO₂ compared to traditional fermentation.
Enzymit is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include cell-free biomanufacturing, hyaluronic acid supplier, ai-designed enzymes, pharma ha production, sustainable biotech.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.enzymit.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- cell-free biomanufacturing, hyaluronic acid supplier, ai-designed enzymes, pharma ha production, sustainable biotech
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What capabilities does Enzymit offer for HA production?
- Enzymit produces ultra-pure hyaluronic acid via a cell-free enzymatic process using AI-designed enzymes, enabling customizable molecular weights from 20 kDa to 4 MDa with ≥99% assay and ≤0.05 EU/mg endotoxin.
- Is Enzymit's process regulatory compliant for pharma?
- Yes, their process is GMP-ready, animal-free, and delivers pharmaceutical-grade HA suitable for APIs, with demonstrated pilot-scale production at 200 liters yielding multi-kilogram quantities.
- What geographies does Enzymit operate in?
- Enzymit is based in Israel (Rehovot/Ness Ziona) with partnerships in the Netherlands (Cosun, NIZO), supporting scalable production for global pharma and cosmetics markets.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
